<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="Research Article" dtd-version="1.0"><front><journal-meta><journal-id journal-id-type="pmc">srjms</journal-id><journal-id journal-id-type="pubmed">SRJMS</journal-id><journal-id journal-id-type="publisher">SRJMS</journal-id><issn>2788-9483</issn></journal-meta><article-meta><article-id pub-id-type="doi">https://doi.org/10.47310/srjms.2024.v0i402.007</article-id><title-group><article-title>A Comprehensive Assessment of Immunological and Biochemical Biomarkers in Patients with Acute Hepatitis B Infection</article-title></title-group><contrib-group><contrib contrib-type="author"><name><given-names>Ali Hussein Ahmed</given-names><surname>Al-Dabbagh</surname></name></contrib><xref ref-type="aff" rid="aff-a" /></contrib-group><contrib-group><contrib contrib-type="author"><name><given-names>Abeer Kamal</given-names><surname>Saleh</surname></name></contrib><xref ref-type="aff" rid="aff-a" /></contrib-group><contrib-group><contrib contrib-type="author"><name><given-names>Sahar  Azmi</given-names><surname>Sdiq</surname></name></contrib><xref ref-type="aff" rid="aff-a" /></contrib-group><contrib-group><contrib contrib-type="author"><name><given-names>Muhannad Abdullah</given-names><surname>Al-Azzawy</surname></name></contrib><xref ref-type="aff" rid="aff-b" /></contrib-group><aff-id id="aff-a">M.Sc. Medical Microbiology-Molecular Biology, Kirkuk Health Directorate, Iraq</aff-id><aff-id id="aff-b">Ph.D. Medical Microbiology, Virology, Kirkuk Health Directorate, Iraq</aff-id><abstract>Acute hepatitis B is a significant viral infection caused by the hepatitis B virus (HBV), affecting the liver and potentially leading to severe liver damage. Monitoring specific serological markers and cytokines is crucial in assessing the immune response and disease progression in patients with acute hepatitis B Aim: This study aims to assess the levels of hepatitis B serological markers (HBsAg, anti-HBc, HBeAg, anti-HBe), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and procalcitonin (PCT) in patients with acute hepatitis B. Materials and methods: A cross-sectional study was conducted in Kirkuk city from June 1, 2023, to July 31, 2024, to evaluate the serological and molecular markers in patients with acute hepatitis B infection. The study included 44 patients aged 20-75 years who were admitted to Hepatology and Gastroenterology centers in Kirkuk. An equal number of healthy controls were selected, matched for age and sex, and were recruited from blood donors. Blood samples were collected from each participant for serological testing of IL-6, TNF-α, IFN-γ, and PCT using ELISA, and for biochemical tests including ALT, AST, ALP, and TSB. Additionally, HBV DNA was isolated using the ZR Viral DNA Kit and quantified using real-time PCR. Results: The study showed a significant prevalence of HBsAg and HBcIgM among all patients, confirming acute HBV infection. The study found that HBeAg-positive patients had significantly higher viral loads compared to HBeAg-negative patients. Biochemical parameters such as ALT, AST, ALP, and TSB were significantly elevated in patients compared to controls, indicating liver inflammation and damage. Inflammatory markers IL-6, TNF-α, and IFN-γ were also significantly higher in patients, highlighting the systemic inflammatory response to acute HBV infection. The study concluded that acute hepatitis B is associated with significant biochemical and inflammatory disturbances, with higher viral loads correlating positively with ALT, TSB, and IL-6 levels. These findings underscore the importance of comprehensive monitoring of viral load and inflammatory markers in the management of acute hepatitis B to improve patient outcomes</abstract></article-meta></front><body /><back /></article>